• SKIP TO CONTENT
  • SKIP NAVIGATION
  • Patient Resources
    • COVID-19 Patient Resource Center
    • Clinical Trials
    • Search Clinical Trials
    • Patient Notification System
    • What is Clinical Research?
    • Volunteering for a Clinical Trial
    • Understanding Informed Consent
    • Useful Resources
    • FDA Approved Drugs
  • Professional Resources
    • Research Center Profiles
    • Clinical Trial Listings
    • Market Research
    • FDA Approved Drugs
    • Training Guides
    • Books
    • eLearning
    • Events
    • Newsletters
    • JobWatch
    • White Papers
    • SOPs
    • eCFR and Guidances
  • White Papers
  • Trial Listings
  • Advertise
  • COVID-19
  • iConnect
  • Sign In
  • Create Account
  • Sign Out
  • My Account
Home » Demonsang, Tobelem join OSE Pharma board, Peyroles named CFO

Demonsang, Tobelem join OSE Pharma board, Peyroles named CFO

November 13, 2013
CenterWatch Staff

OSE Pharma, dedicated to severe and orphan lung diseases, has announced the nomination of two new board members with a broad international experience and the recruitment of a CFO from the healthcare industry. These appointments are part of the plan to launch phase III of its targeted lung cancer immunotherapy product.

The targeted immunotherapy (OSE2101) is developed for patients with advanced lung cancer (non-small cell lung cancer) and phase III is in preparation. OSE 2101 is activating the T cytotoxic lymphocytes, enabling them to kill the tumor cells expressing the tumor antigens. This major innovative immune therapy is presenting a new hope for cancer patients.  

Jean-Patrick Demonsang will join OSE Pharma as a board member. Former president of Seventure Partners, he successfully oversaw more than 150 companies mainly involved in information technologies and life sciences. Over the last 25 years, as an entrepreneur, Demonsang founded and managed numerous SMEs’ companies as chairman and CEO.

Professor Gérard Tobelem also will become a board member. He is the winner of the 2006 Diderot Innovation Prize. Tobelem held numerous senior positions at the French Ministry of Research and Higher Education and served as executive chairman of the French national blood transfusion service (Etablissement Français du Sang). He also worked as a consultant for the R&D divisions of multinational pharmaceutical companies for several years. He currently is non-executive chairman of the French company Theradiag. He is former professor of hematology at Paris VII University and the former head of the hematology department at Lariboisière Hospital (Paris).

On the operational side, Alexis Peyroles is joining OSE Pharma as CFO. Peyroles has more than 15 years of international experience in the Pharma industry, working for Sanofi then Guerbet in finance or general management.

Upcoming Events

  • 25May

    2022 WCG Avoca Quality & Innovation Summit: Own the Future

  • 28Jun

    Effective Root Cause Analysis and CAPA Investigations for the Life Sciences

  • 16Oct

    WCG MAGI's Clinical Research Hybrid Conference - 2022 West

Featured Products

  • Spreadsheet Validation: Tools and Techniques to Make Data in Excel Compliant

    Spreadsheet Validation: Tools and Techniques to Make Data in Excel Compliant

  • Surviving an FDA GCP Inspection

    Surviving an FDA GCP Inspection: Resources for Investigators, Sponsors, CROs and IRBs

Featured Stories

  • Protocol-360x240.png

    Avoid Deviations by Making Protocol Review a Team Effort

  • SelectionProcess-360x240.png

    Give Us a Voice: Sites Clamor for a Say on Vendor Selection

  • Convince-360x240.png

    Use Data and Details to Convince Site Leadership to Add Staff

  • AsktheExpertsBadge-360x240.png

    Ask the Experts: Listing Trial Staff and Others on the Statement of Investigator

Standard Operating Procedures for Risk-Based Monitoring of Clinical Trials

The information you need to adapt your monitoring plan to changing times.

Learn More Here
  • About Us
  • Contact Us
  • Privacy Policy
  • Do Not Sell My Personal Information

Footer Logo

300 N. Washington St., Suite 200, Falls Church, VA 22046, USA

Phone 617.948.5100 – Toll free 866.219.3440

Copyright © 2022. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing